CMS’ Use Of Data From “Coverage With Evidence Development” Process To Vary
This article was originally published in The Pink Sheet Daily
Executive Summary
The way data are used will depend on whether information is gathered through a clinical trial, registry or other method, CMS’ Phurrough says. Most data collection methods will not support a change in a national coverage determination, although such information will assist in clinical practice.
You may also be interested in...
CMS Colorectal Cancer Drug Policy Will Not Limit Current Off-Label Coverage
The Centers for Medicare & Medicaid Services releases its final national coverage determination for Avastin, Erbitux, Eloxatin and Camptosar. The final determination is in line with the draft NCD, covering off-label indications that are included in certain major compendia and are part of nine National Cancer Institute clinical trials.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said